Redox-active iron mediates amyloid-beta toxicity

Free Radic Biol Med. 2001 Feb 15;30(4):447-50. doi: 10.1016/s0891-5849(00)00494-9.

Abstract

While amyloid-beta toxicity is mediated by oxidative stress and can be attenuated by antioxidants, the actual biochemical mechanism underlying neurotoxicity remains to be established. However, since aggregated amyloid-beta can interact with transition metals, such as iron, both in vitro and in vivo, we suspected that bound iron might be the mediator of toxicity such that holo- and apo-amyloid would have differential effects on cellular viability. Here we demonstrate that when amyloid-beta is pretreated with the iron chelator deferoxamine, neuronal toxicity is significantly attenuated while conversely, incubation of holo-amyloid-beta with excess free iron restores toxicity to original levels. These data, taken together with the known sequelae of amyloid-beta, suggest that the toxicity of amyloid-beta is mediated, at least in part, via redox-active iron that precipitates lipid peroxidation and cellular oxidative stress.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amyloid beta-Peptides / toxicity*
  • Antioxidants / pharmacology*
  • Cell Death / drug effects
  • Deferoxamine / pharmacology
  • Humans
  • Iron / physiology*
  • Neuroblastoma
  • Neurons / drug effects*
  • Neurons / metabolism
  • Oxidative Stress
  • Tumor Cells, Cultured

Substances

  • Amyloid beta-Peptides
  • Antioxidants
  • Iron
  • Deferoxamine